Indian startup 4baseCare is stepping into Dubai with its precision oncology and to make it accessible to the global market. The company is backed by Illumina Accelerator and mainly known for its advanced genomics solutions. It is reshaping cancer treatment by personalizing therapy through genomics and digital health technologies. It is expanding footprint across Southeast Asia and the Middle East by establishing a state-of-the-art genomics lab in Dubai Science Park by collaborating with Innovate Life Sciences.
The expansion has been partly fueled by a recent $6 million funding round from Yali Capital. It highlights investors’ confidence in the transformative potential of personalized cancer care. It has enabled the company to expand reach into Dubai and simultaneously also laid the groundwork for international ventures.
The new genomics lab of 4baseCare will provide sophisticated genomic testing solutions such as cancer gene panels, whole exome sequencing and transcriptome analysis. The tools offer oncologists deeper insights into tumor genetics. It tailors treatments that can potentially improve outcomes for cancer patients. The startup is building a bridge between complex genomic data and practical with the lab.
4baseCare also lately introduced a next-generation sequencing (NGS) testing solution named SoLiq. It combines solid as well as liquid biopsy technologies and the innovation provides a 360° view of tumor biology. It enables the oncologists to assess tumors from multiple perspectives and craft treatment plans.
Choosing Dubai for expansion hub means gaining access to a region that is known for its healthcare innovation and also signals a broader mission to make precision oncology a global standard in cancer care. 4baseCare is setting the stage for a future where personalized cancer therapy becomes the norm rather than the exception.
